Comparative Pharmacology
Head-to-head clinical analysis: FORTESTA versus HALOTESTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTESTA versus HALOTESTIN.
FORTESTA vs HALOTESTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
Fluoxymesterone is a synthetic androgen that binds to androgen receptors, activating gene transcription and promoting protein synthesis, leading to anabolic and androgenic effects.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
10-20 mg orally three to four times daily for replacement therapy; 2-10 mg orally daily for delayed puberty in males.
None Documented
None Documented
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Terminal elimination half-life: 9.6 hours. Clinical context: Steady-state achieved after ~48 hours.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Renal: 90% as glucuronide and sulfate conjugates; fecal: 10%.
Category C
Category C
Androgen
Androgen